Analysts Set Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Price Target at $41.75

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has received a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $41.75.

Several analysts have weighed in on COAG shares. Jefferies Financial Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Wedbush initiated coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective on the stock.

Insider Activity

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock in a transaction that occurred on Monday, May 4th. The shares were bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This represents a 77.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have bought a total of 2,902,872 shares of company stock worth $53,769,784 in the last 90 days.

Hemab Therapeutics Price Performance

NASDAQ COAG opened at $27.47 on Friday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.